3DPS logo
3DPS Europe
Service and development
News

News / article

Life sciences
← Back to news Back to homepage
Bioactivx and UltiMaker: 3D Printing in Regulated Skin-Substitute Manufacturing
2026. 09. 28.
825

Bioactivx and UltiMaker: 3D Printing in Regulated Skin-Substitute Manufacturing

1 min read

The Singapore project shows how FFF can become part of a regulated manufacturing workflow for medical end products.

What is being made?

Bioactiv Matrix is a synthetic skin substitute; the company uses proprietary filament and a controlled printing process.

Regulatory context

The report cites Singapore HSA approval and operations under ISO 13485. This does not imply automatic approval in other jurisdictions.

Why it matters

Additive manufacturing is part of a documented and controlled production process rather than a demonstration prototype.

Sources

Related articles
Archive

Earlier news

79 earlier article(s)